Physician profile
Alma M Devine
NPI 1447487681
$1,401.15
in general payments reported to CMS, 2019-2025
20 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $21.21 · 2024: $145 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $206.13 | 2025 | Isturisa |
| Renalytix Ai, INC. | $186.71 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Novo Nordisk INC | $159.29 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amneal Pharmaceuticals LLC | $155.33 | 2025 | Unithroid |
| Echosens North America, INC. | $104.17 | 2025 | Fibroscan |
| Alexion Pharmaceuticals, INC. | $91.60 | 2024-2025 | Strensiq |
| Lilly USA, LLC | $74.00 | 2025 | Mounjaro, Jardiance, Zepbound |
| Inspire Medical Systems, INC. | $63.07 | 2025 | Inspire |
| Corcept Therapeutics | $61.81 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.93 | 2024-2025 | Jardiance |
| Beta Bionics, INC. | $42.24 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Madrigal Pharmaceuticals | $34.49 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $29.45 | 2024 | Injectafer |
| Amphastar Pharmaceuticals, INC. | $21.85 | 2025 | |
| Dexcom, INC. | $21.21 | 2023 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $19.90 | 2025 | Dupixent |
| Xeris Pharmaceuticals, INC. | $19.38 | 2025 | Gvoke Hypopen |
| Intra-Sana Laboratories | $18.02 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Ascendis Pharma Endocrinology INC | $17.44 | 2025 | Yorvipath |
| Novartis Pharmaceuticals Corporation | $17.13 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alma Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.